PET IMAGING IN UROLOGY: Edited by Stefano Fanti and Declan G. MurphyProstate-specific membrane antigen PET/computed tomography for staging prostate cancerRavi Kumar, Aravind S.a,b; Lawrentschuk, Nathanc,d,e; Hofman, Michael S.a,b,fAuthor Information aMolecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre bSir Peter MacCallum Department of Oncology, University of Melbourne cEJ Whitten Prostate Cancer Research Centre at Epworth Hospital dRoyal Melbourne Department of Urology and Peter MacCallum Cancer Centre eDepartment of Surgery, University of Melbourne, Melbourne, Australia fProstate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) Correspondence to Aravind S. Ravi Kumar, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia. Tel: +61 3 8559 5000; e-mail: email@example.com Current Opinion in Urology: September 2020 - Volume 30 - Issue 5 - p 628-634 doi: 10.1097/MOU.0000000000000799 Buy Metrics Abstract Purpose of review Molecular imaging with PET/CT targeting the prostate-specific membrane antigen (PSMA) receptor is increasingly utilized in men with prostate cancer (PCa), with clinical indications now expanding beyond biochemical recurrence. PSMA PET/CT often detects sub-centimetre size pathologic nodes and low-volume bone marrow disease that are occult on conventional imaging when the lesion does not cause sclerosis or osteoblastic reaction in surrounding bone. This review focuses on recent evidence for PSMA PET/CT in initial disease staging. Recent findings Several recent studies including a large randomized trial have evaluated the clinical impact of PSMA PET/CT in initial staging of PCa. PSMA PET/CT is more sensitive and accurate than the conventional imaging standard of CT and bone scan. Change in treatment plan or modality of therapy occurs frequently when PSMA PET/CT forms part of the diagnostic algorithm. Hybrid PET/MRI also has potential utility, particularly in evaluating pelvic disease, but evidence base remains very limited. Summary PSMA PET/CT has emerged as a new standard in primary staging of PCa. Reimbursement by national funding bodies and incorporation into international clinical guidelines is anticipated within the next few years. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.